Illumina, Inc. $ILMN Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System grew its position in Illumina, Inc. (NASDAQ:ILMN) by 16,869.5% in the second quarter, HoldingsChannel reports. The fund owned 40,144,099 shares of the life sciences company’s stock after acquiring an additional 39,907,533 shares during the quarter. California State Teachers Retirement System owned 0.27% of Illumina worth $7,058,537,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Elyxium Wealth LLC acquired a new position in Illumina in the 4th quarter worth about $25,000. Fiduciary Financial Advisors acquired a new stake in Illumina in the second quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina in the second quarter valued at approximately $32,000. Quarry LP purchased a new stake in shares of Illumina in the third quarter valued at approximately $32,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $33,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: S&P 500 inclusion should support demand. Illumina will join the S&P 500 before the market opens on September 21, moving up from the S&P MidCap 400. The change is expected to generate buying from index-tracking funds and increase the company’s visibility among institutional investors. Illumina and Everpure to Join S&P 500 in September Rebalancing
• Positive Sentiment: Analyst sentiment has improved. Zacks upgraded Illumina to Rank #2, or “Buy,” citing greater optimism about its earnings outlook. The upgrade could provide additional short-term momentum. Illumina Upgraded to Buy
• Positive Sentiment: Business quality remains a bullish theme. Commentary highlights Illumina’s leadership in gene sequencing and the expanding use of genomics in diagnostics and precision medicine. Investors are weighing whether continued operational strength can justify the stock’s recent advance. ILMN Stock Keeps Climbing

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. TD Cowen increased their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Citigroup increased their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a report on Monday, August 3rd. Finally, Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $191.31.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $211.06 on Wednesday. The firm has a 50-day simple moving average of $199.86 and a 200-day simple moving average of $160.68. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $31.87 billion, a price-to-earnings ratio of 39.38, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the business posted $1.19 earnings per share. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 2,062,465 shares of company stock worth $436,589,802. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.